Drug name - Lumigan

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

CN101137383A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292A ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN101137383B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

CN102240292B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

IN263623B ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

IN200706652P1 ALLERGAN Enhanced Bimatoprost Opthalmic Solution
Mar, 2026

(3 years from now)

EP1753434A2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B1 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

EP1753434B2 ALLERGAN Enhanced Bimatoprost Ophthalmic Solution
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of lowering intraocular pressure; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.01% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.